Coulter Partners places seasoned financial leader David Hastings as CFO at Trevi Therapeutics
LONDON, UK and CAMBRIDGE, MA – January 13, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for Trevi Therapeutics, Inc. (Nasdaq: TRVI) and is pleased to announce the placement of David Hastings as Chief Financial Officer (CFO).
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC).
David Hastings brings over 25 years of financial leadership in the public life sciences and biopharmaceutical sectors to Trevi. His expertise spans capital raising, commercialization, and investor relations, having secured over $2 billion in equity and debt financing throughout his career. Most recently, Mr. Hastings served as CFO at Arbutus. He previously spent over a decade as CFO and Executive Vice President at Incyte, where he managed the company’s transition from R&D to commercialization following the launch of Jakafi®. During his tenure, he scaled the organization to over 700 employees and co-led major out-licensing deals. Mr. Hastings has also held CFO roles at Unilife and ArQule Inc. and currently chairs the Audit Committee for Scynexis, Inc.
“I am thrilled to welcome Dave to the leadership team as we enter an important chapter of growth at Trevi,” said Jennifer Good, President and CEO of Trevi Therapeutics. “His proven track record and experience as we transition into Phase 3 development and beyond will be critical as we continue to advance Haduvio for the treatment of chronic cough.
“Filling this critical role required a search partner that could balance a thorough, robust process with a real sense of urgency, and Coulter Partners delivered on both counts,” added Jennifer Good. “From the very beginning, the Coulter team demonstrated a deep understanding of our specific requirements and the Trevi culture. They worked in close partnership with us, leveraging their extensive network and assessment expertise to provide invaluable insights on prospective candidates. Ultimately, we relied on their trusted advice to identify the right fit for our team, and we are thrilled to welcome a leader of Dave’s caliber to Trevi.”
David Hastings, Chief Financial Officer at Trevi Therapeutics, Inc.
Mr. Hastings brings over 25 years of financial leadership in public life sciences and biopharmaceutical companies to Trevi. His accomplishments span capital raising, commercialization, business development, and investor relations management. Throughout his career, Mr. Hastings has raised over $2B in equity and debt financing. Most recently, Mr. Hastings was Chief Financial Officer (CFO) at Arbutus from June 2018 until March 2025. Previously, he was Senior Vice President and CFO of Unilife from 2015 until 2017. Prior to that, he spent the majority of his career as CFO and Executive Vice President at Incyte, a role he held from 2003 to 2014. During his tenure at Incyte, Mr. Hastings oversaw all financial aspects of the company’s transition from research and development to commercialization following the launch of Jakafi® (ruxolitinib). He was integral in managing the financial and operational complexities of scaling the company to over 700 individuals. Additionally, he co-led the negotiation of two out-licensing deals for two compounds. Mr. Hastings also previously served as Vice President, CFO and Treasurer at ArQule Inc., where he played an important role in the company’s transition into a drug discovery and development organization, and in its two strategic acquisitions, including the purchase of Cyclis Pharmaceuticals Inc. Currently, Mr. Hastings is a Board member and Chair of the Audit Committee of Scynexis, Inc.
[ENDS]
Notes to editors:
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies.
There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough.
Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients’ quality of life.
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com
About Coulter Partners
We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.
